Skip to main content
Premium Trial:

Request an Annual Quote

Daniel Marshak, Gene Logic, Affymetrix, Signature Genomic Laboratories, CombiMatrix

Premium

People in the News

PerkinElmer has appointed Daniel Marshak as vice president and chief scientific officer. Marshak will be responsible for PerkinElmer's R&D strategy, and for "helping drive its growth strategies in the emerging areas of personalized medicine and predictive diagnostics," the company said in a statement.

Marshak joins the firm from Cambrex, where he was vice president and CTO. He currently serves as an adjunct associate professor at Johns Hopkins University School of Medicine and is also an advisor to PharmaFrontiers.

Marshak holds a PhD from Rockefeller University and a BA in biochemistry and molecular biology from Harvard University.

 

New Product Watch

Gene Logic this week said that it has added SNP genotyping to its data generation and analysis services capabilities:

The company said that its new service is ideal for researchers that are conducting disease-association studies or involved in drug discovery and development.

Gene Logic exclusively uses Affymetrix GeneChips in its services.


Signature Genomic Laboratories last week announced the availability of its SignatureChip Version 4.0 microarray for immediate use in its clinical diagnostic testing services.

According to the Spokane, Wash.-based cytogenetic analysis service, SignatureChip Version 4.0 provides a total of 1887 BAC clones and 622 contigs representing over 64 recognized genetic syndromes, plus all 41 subtelomeres, and all 43 pericentromeric regions.

The company said that it will not raise the price for its services, despite the increase in content. Signature is also offering current customers the ability to retest any samples that it has shown to have a subtelomere abnormality identified by a previous version of the SignatureChip at no extra charge, the company added.


CombiMatrix last week launched an updated version of its Influenza A Typing Microarray. The upgraded array now includes sequences that had not been previously available, the company said.

The Influenza A Typing Microarray is a component of the company's Electrochemical Influenza Surveillance System that CMBX claims can identify all strains of Influenza A, including bird and human varieties. In addition, CBMX claims the system can detect mixed or multiple infections of influenza.


Stone Bond Technologies has launched its new Affymetrix GeneChip-Compatible Instrument Interface Suite, a laboratory information management system.

Stone Bond said that the new LIMS is powered by its Enterprise Enabler tool and can automate sample registration, track sample processing, and reagent inventory as well as manage resultant data outflow from any Affymetrix GeneChip processing systems.

The company said that the suite is compatible with its EE-LIMS Web-based laboratory information management system, which has been achieved Affymetrix GeneChip-Compatible status.

The suite can be purchased as a component of Stone Bond's EE-LIMS solutions package, or as a stand-alone module which can be integrated to work with other LIMS environments, Stone Bond said.


Gentris last month announced the availability of Human Genomic DNA Reference Controls for the Cytochrome P450 2D6 gene.

The company said that its controls can be used in microarray-based assays that monitor the Cytochrome P450 2D6 gene. Gentris added that the controls are available for research use only at this time. The company said it intends to offer reference controls for additional genes in the future including CYP2C9, CYP2C19 and UGT1A1.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.